Torcetrapib: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk (new stub with pix) |
imported>David E. Volk (increased death and cardiac events) |
||
| Line 9: | Line 9: | ||
|uses=cardiac medication | |uses=cardiac medication | ||
|properties= | |properties= | ||
|hazards= | |hazards=increased death and cardiac events | ||
|iupac= see chemistry section | |iupac= see chemistry section | ||
|casnumber= 262352-17-0 | |casnumber= 262352-17-0 | ||
}} | }} | ||
Torcetrapib | Torcetrapib was a drug in development to be used to modulate cholesterol levels by its inhibition of [[cholesteryl ester transferase protein]] (CETP). Pfizer announces its withdrawal of torcetrapib from development<ref> ulr=http://www.pfizer.com/pfizer/download/investors/financial/8k_1202_06.pdf</ref> Although torcetrapib quickly raised HDL [[cholesterol]] in the ILLUMINATE study, patients receiving both torcetrapib and [[atorvastatin]] has increased incidence of adverse cardiac events and death compared to the control group only receiving atorvastin. Similar medications include [[anacetrapib]] and [[dalcetrapib]]. | ||
== Chemistry == | == Chemistry == | ||
The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. | The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester. | ||
Revision as of 11:19, 26 November 2010
|
| |||||||
| torcetrapib | |||||||
| |||||||
| Uses: | cardiac medication | ||||||
| Properties: | |||||||
| Hazards: | increased death and cardiac events | ||||||
| |||||||
Torcetrapib was a drug in development to be used to modulate cholesterol levels by its inhibition of cholesteryl ester transferase protein (CETP). Pfizer announces its withdrawal of torcetrapib from development[1] Although torcetrapib quickly raised HDL cholesterol in the ILLUMINATE study, patients receiving both torcetrapib and atorvastatin has increased incidence of adverse cardiac events and death compared to the control group only receiving atorvastin. Similar medications include anacetrapib and dalcetrapib.
Chemistry
The chemical name of torcetrapib is (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester.